Best GLP-1 Providers in Illinois (2026)

See by medication

Looking for a specific GLP-1? Browse Illinois providers by drug.

About GLP-1s in Illinois

Illinois has a strong telehealth framework for GLP-1 prescribing. Illinois Medicaid (HFS) covers GLP-1s for both diabetes and obesity with prior authorization.

• •Illinois's adult obesity rate is 32.4%
• •Illinois Medicaid covers GLP-1s with prior authorization
• •Chicago is one of the largest telehealth GLP-1 markets in the Midwest

Top Cities for GLP-1 Treatment in Illinois

Telehealth providers ship to all Illinois addresses, but demand is highest in these metro areas:

Prefer an in-person clinic? Browse the Illinois GLP-1 clinic directory →

GLP-1 Care Access in Illinois: The Numbers

Illinois has 1,093 NPI-registered in-person weight-management clinics across 193 cities — 19 with an obesity-medicine taxonomy, 539 endocrinology, and 549 bariatric — alongside 101 telehealth programs that ship to Illinois addresses. The cheapest verified ongoing compounded semaglutide price available to Illinois residents is $79/mo (tirzepatide: $97/mo). Full methodology and the 50-state table: GLP-1 care access by state.

Insurance & Medicaid in Illinois

In Q1 2026, Illinois Medicaid reimbursed approximately $55,278,302 across 52,093 GLP-1 prescriptions (all covered indications, gross before rebates — federal SDUD data; full state series here).

Most insurance plans in Illinois cover GLP-1s for type 2 diabetes (Ozempic, Mounjaro), but coverage for obesity-only indications (Wegovy, Zepbound) is much more limited and often requires prior authorization. If your insurance won't cover brand-name GLP-1s, compounded semaglutide through telehealth is typically the most affordable option at around $209/mo.

For the exact criteria, drug list, and appeal process, read our Illinois Medicaid GLP-1 coverage & prior-authorization guide. For coverage backdoors, Zepbound is FDA-approved for obstructive sleep apnea, and Wegovy for kidney and cardiovascular indications, which some plans cover even when they exclude weight-loss-only use.

Obesity in Illinois

According to CDC data, 32.4% of Illinois adults have obesity (BMI of 30 or higher). This places Illinois at #26 out of 50 states. Access to GLP-1 medications like semaglutide and tirzepatide has expanded significantly through telehealth, helping Illinois residents get clinically supervised weight loss treatment from home.

To choose a medication, compare the clinical-trial results behind each drug, see our best semaglutide and tirzepatide provider rankings, or track the next-generation GLP-1 pipeline.

Frequently Asked Questions